Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 6/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | XBP1 | P17861 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067374 | 0.86 | TRPM8 (0.38) | GRIN1GRIN2BKDM4EUSP2ALDH1A1 | |
| SCHEMBL3070814 | 0.81 | APP (0.34) | GRIN1GRIN2B | |
| SCHEMBL3068576 | 0.81 | TP53 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL3060545 | 0.78 | PDE10A (0.33) | — | |
| SCHEMBL13547840 | 0.76 | PDE10A (0.31) | — | |
| SCHEMBL3066024 | 0.76 | RPS6KA5 (0.41) | KDM4EUSP2ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL3060221 | 0.76 | CYP11B1 (0.38) | GRIN1GRIN2BKDM4EALDH1A1CYP11B1 | |
| SCHEMBL13089683 | 0.75 | PTGER4 (0.33) | — | |
| SCHEMBL3066093 | 0.75 | ALDH1A1 (0.40) | GRIN1GRIN2BKDM4EUSP2ALDH1A1 | |
| SCHEMBL3050193 | 0.74 | TP53 (0.39) | KDM4EHTTNPSR1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | claimed |
| EP-1368342-B3 | BENZIMIDAZOLE AND PYRIDYLIMIDAZOLE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS | NEUROGEN CORP (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2010-10-21 | — | — | US | disclosed |
| US-7642267-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2010-01-05 | — | — | US | disclosed |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | NEUROGEN CORPORATION | 2008-09-18 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300945-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2007-11-27 | — | — | US | disclosed |
| EP-1789471-A1 | SULFONATED COPOLYETHERESTER COMPOSITIONS FROM HYDROXYALKANOIC ACIDS AND SHAPED ARTICLES PRODUCED THEREFROM | E.I.Du pont de nemours and company (US) | 2007-05-30 | — | — | EP | disclosed |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION | 2006-02-02 | — | — | US | disclosed |
| WO-2006010062-A1 | SULFONATED COPOLYETHERESTER COMPOSITIONS FROM HYDROXYALKANOIC ACIDS AND SHAPED ARTICLES PRODUCED THEREFROM | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
| US-6916819-B2 | Benzimidazole and pyridylimidazole derivatives | NEUROGEN CORPORATION (US) | 2005-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267698-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | GRIN1 231/4885GRIN2B 111/4885KDM4E 1996/4885 |
| US-20080227793-A1 | Benzimidazole and Pyridylimidazole Derivatives | GABBR1, GABBR2, GABRA2 | GRIN1 231/4885GRIN2B 111/4885KDM4E 1996/4885 |
| US-20060025425-A1 | Benzimidazole and pyridylimidazole derivatives | GABBR1, GABBR2, GABRA2 | GRIN1 231/4885GRIN2B 111/4885KDM4E 1996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.